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Infection caused by Mycobacterium avium is common in AIDS patients who do not receive treatment with highly active antiret-
roviraltherapy(HAART)orwhodevelopresistancetoanti-HIVtherapy.Meﬂoquine,aracemicmixtureusedformalariapro-
phylaxis and treatment, is bactericidal against M. avium in mice. MICs of ()-erythro-, ()-erythro-, ()-threo-, and ()-
threo-meﬂoquinewere32 g/ml,32g/ml,64g/ml,and64g/ml,respectively.Thepostantibioticeffectfor()-erythro-
meﬂoquinewas36h(MIC)and41hforaconcentrationof4MIC.Themeﬂoquinepostantibioticeffectwas25h(MICand4
MIC).Afterbaselineinfectionwasestablished(7days),the()-and()-isomersofthediastereomericthreo-anderythro--(2-
piperidyl)-2,8-bis(triﬂuoromethyl)-4-quinolinemethanolwereindividuallyusedtoorallytreatC57BL/6bg
/bg
beigemicethat
were infected intravenously with M. avium. Mice were also treated with commercial meﬂoquine and diluent as controls. After 4
weeksoftreatment,themicewereharvested,andthenumberofbacteriainspleenandliverwasdetermined.Micereceiving()-
or()-threo-meﬂoquineor()-erythro-meﬂoquinehadnumbersofbacterialloadintissuessimilartothoseofuntreatedcon-
trolmiceat4weeks.Commercialmeﬂoquinehadabactericidaleffect.However,micegiventhe()-erythro-enantiomerfor4
weekshadasigniﬁcantlygreaterreductionofbacterialloadthanthosegivenmeﬂoquine.Thus,()-erythro-meﬂoquineisthe
active enantiomer of meﬂoquine against M. avium and perhaps other mycobacteria.
M
ycobacteriumaviumisacommoncauseofdisseminateddis-
ease in patients with an advanced stage of AIDS (1, 16).
Despite the advent of effective anti-HIV-1 therapy, M. avium in-
fection is still seen in individuals who develop resistance to anti-
viral therapy or who interrupt therapy. M. avium is also the cause
of lymphadenopathy in children and lung disease in the elderly
and in patients with chronic lung disease (11). In addition, many
individualsdevelopM.aviumdiseasebecausetheyhaveanunder-
lying immunodeﬁciency, such as a lack of gamma interferon
(IFN-) receptor or interleukin 12 (IL-12) receptor (2, 10). A
limited number of compounds, such as macrolides (clarithromy-
cin, azithromycin), ethambutol, and amikacin, have demon-
strated therapeutic utility against M. avium in humans. A quino-
lone, moxiﬂoxacin, has been used for M. avium treatment,
although despite experimental studies in vivo (5), the evidence of
efﬁcacy in humans is only anecdotal at this point. The limited
therapy available to treat M. avium infection emphasizes the need
for additional drugs with anti-M. avium efﬁcacy.
Severalyearsago,afterscreeningalibraryofcompoundsforM.
avium activity, we identiﬁed meﬂoquine, a compound with anti-
plasmodium activity, as one with promising activity against M.
avium (7). Although the MIC of meﬂoquine in vitro is approxi-
mately 16 g/ml (most mycobacterial isolates), its capacity to
concentrate intracellularly severalfold makes it bactericidal
againstM.aviuminvivo(6,7).Meﬂoquinecanbeincludedaspart
of a triple-drug regimen alternative to macrolide-containing reg-
imens for treatment of M. avium (6). Meﬂoquine has an additive
effect when administered together with moxiﬂoxacin (6).
Meﬂoquine, however, has side effects, primarily neuropsychi-
atric effects, as reported in individuals receiving meﬂoquine pro-
phylaxis (19); the risk of serious neuropsychiatric adverse effects
during prophylaxis is estimated to be 1/10,600. Meﬂoquine, -2-
piperidinyl-2,8-bis(triﬂuoromethyl)-4-quinolinemethanol, is an
antimalarial agent (Lariam) administered orally as the racemic
mixtureofthetwoerythro-enantiomers()-11R,2=S-meﬂoquine
[()-meﬂoquine] and ()-11S,2=R-meﬂoquine [()-meﬂo-
quine], two threo-enantiomers. Since side effects and anti-M.
avium activity could be the property of different enantiomers, we
decided to isolate the optical enantiomers of meﬂoquine—the
()- and ()-erythro-meﬂoquine and the ()- and ()-threo-
meﬂoquine—and evaluate the activity of each enantiomer indi-
viduallyinmice.Wealsoevaluatedthepostantibioticeffectofthe
meﬂoquine enantiomer ()-erythro-meﬂoquine in comparison
with meﬂoquine and clinically used compounds, as well as per-
formed pharmacokinetic assays. The results indicate that ()-
erythro-meﬂoquine is the active enantiomer in vivo.
MATERIALS AND METHODS
Mycobacterium. MAC 101 (serotype 1), originally isolated from the
blood of an AIDS patient, is a well-characterized human isolate that has
beenusedextensivelyinmanypreviousstudies(6,7).MAC100,104,108,
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 109, and 116 were also isolated from the blood of AIDS patients and
belongtoserotypes8,1,1,4,and1,respectively.M.aviumorganismswere
cultured on Middlebrook 7H11 agar (Difco, Detroit, MI) supplemented
witholeicacid,albumin,dextrose,andcatalasefor10daysat37°C.Forthe
infection of mice, transparent colony morphotypes were harvested and
resuspended in Hank’s buffered salt solution (HBSS) and adjusted to a
concentration of 3  10
8 CFU/ml by using a McFarland standard (5, 6).
Thenumberofbacteriaintheinoculumwasconﬁrmedbycolonyplating
onto 7H11 agar. Thirty clinical isolates, including MAC 100, 104, 108,
109,and116,wereusedfortheMICassay.Sixoftheisolateswereresistant
to clarithromycin.
Antibiotics. The racemic mixture of meﬂoquine was provided by the
Walter Reed Army Institute for Research. Racemic meﬂoquine hydro-
chloride was resolved using the ammonium salt of ()-3-bromo-8-cam-
phorsulphuric acid to afford ()-erythro-meﬂoquine, as previously de-
scribed (9). In an analogous fashion, ()-erythro-meﬂoquine was
obtained using the ammonium salt of ()-3-bromo-8-camphorsulphu-
ric acid. Each of the erythro-enantiomers was epimerized to the corre-
spondingthreo-enantiomerbytreatmentofeachN-acetylderivativewith
thionyl chloride as reported previously (9). The erythro and threo-enan-
tiomers of meﬂoquine were provided by the Walter Reed Army Institute
of Research under NIAID contract N01-AI-5402.
In vitro testing. MICs were performed by a radiometric broth mac-
rodilution method and the T100 method of data analysis (15). The inoc-
ulum was prepared as previously reported (15). It was placed into 7H9
broth and frozen at 70°C. The bacterial concentration was adjusted to
approximately 5  10
4 CFU/ml as previously described (15). Controls
included the inoculum undiluted without adding drug, the inoculum di-
luted1:100(99%control),andtheinoculumdiluted1:1,000(99.9%con-
trol). The period of observation and the endpoint were determined by
dailymonitoringofthecontrolandtestcultures.Sevendayswassufﬁcient
time for the isolates.
Postantibiotic effect. The postantibiotic effect of meﬂoquine, enan-
tiomers, clarithromycin, and moxiﬂoxacin was determined as previously
described (8) against the strains MAC 101, MAC 104, and MAC 109. The
postantibiotic effect for meﬂoquine, as well as that for ()-erythro-me-
ﬂoquine,wasidentiﬁedinparalleltothepostantibioticeffectofclarithro-
mycin and moxiﬂoxacin, using the MIC and 4 MIC.
Mouse studies. C57BL/6J-Lyst
bj-J/Lyst
bj-J female mice, age 8 to 10
weeks, were obtained from Jackson Laboratories for challenge studies.
Micewereinfectedthroughthecaudalveinwith310
7CFUofMAC101
in a volume of 0.1 ml. After 7 days, treatment was initiated with meﬂo-
quine, ()-erythro-meﬂoquine, ()-erythro-meﬂoquine, ()-threo-
meﬂoquine, or ()-threo-meﬂoquine at 40 mg/kg of body weight/day as
oral monotherapy. The dose was determined based on a previous study
that evaluated the dose-response activity of meﬂoquine (7). Each drug
treatment group in each experiment contained at least 12 animals. Con-
trol groups, also with 12 animals each, received the drug vehicle only. In
addition,anexperimentalgroupofatleastﬁvemicewasharvestedafter7
days of infection, in order to establish a baseline level of infection in
tissues. Mice received treatment for 4 weeks and were then euthanized
after a period of 48 h without receiving therapy. Livers and spleens of all
mice were aseptically dissected, weighed, and homogenized in 5 ml of
Middlebrook 7H9 broth (Difco) containing 20% glycerol, as previously
described (6, 7). Tissue suspensions were serially diluted and plated onto
Middlebrook 7H11 agar plates to determine the number of viable organ-
isms. Plates were incubated at 37°C for 10 days.
Bactericidal effect was deﬁned as the bacterial load at the end of the
experimentbeingsmallerthanthebacterialloadatdayseven,beforetreat-
ment was initiated.
Blood drug levels. Blood concentrations were determined after a sin-
gle-dose oral administration of 10 mg/kg of meﬂoquine and each of the
enantiomers, ()-erythro, ()-erythro, ()-threo, and ()-threo to
BALB/c mice. Blood was collected from the retro-orbital sinus into tubes
containingEDTAat10min,30min,1h,2h,4h,8h,12h,24h,3days,and
5 days after oral administration. Blood was also obtained from control,
untreatedmice.Between18and21micewereusedperdrugforeachtime
point.Collectedbloodwasfrozenuntilanalysisbyhigh-performanceliq-
uid chromatography (HPLC).
Onehundredmicrolitersofthawedbloodsamplesorcalibrationstan-
dards received 20 l of internal standard solution (see Table 3), followed
by 100 l of 0.2 N NaOH. Meﬂoquine analogs were extracted from the
bloodwith1,000lmethylt-butylether(MTBE).Theorganiclayerswere
removed, and the MTBE was evaporated. Meﬂoquine derivatives in the
resultingdryresidueswerederivatizedbytheadditionof125lof0.4mM
()-1-(9-ﬂuorenyl)ethyl chloroformate (FLEC) diluted in acetonitrile
and 50 l of 15 mM sodium borate buffer, pH 8.5, to form a ﬂuorescent
derivative of these analytes. The mixtures were incubated at room tem-
perature for 40 min and then clariﬁed by centrifuging for 5 min before
beingtransferredtoHPLCvialsﬁttedwithglassinsertsforHPLCanalysis.
Meﬂoquine, ()-erythro, ()-erythro, ()-threo, and ()-threo
were assayed using ()-threo, ()-erythro, ()-erythro, ()-threo, and
()-threo, respectively, as internal controls.
ThemeﬂoquineanalogswereseparatedbyHPLC,usingaC18column
(Luna C18 [2], 4.6 by 250 mm, from Phenomenex, Torrance, CA) main-
tainedatroomtemperature.Elutionoftheanalogswasachievedisocrati-
cally with 74% acetonitrile-26% water (vol/vol) containing 0.1% formic
acidataﬂowrateof1ml/minforatotalruntimeof40min.Theautosam-
pler temperature was controlled at 10°C. Injection volumes of all samples
and standards were 20 l. Chromatography was monitored by ﬂuores-
cence with excitation at 265 nm and emission at 475 nm, and under these
conditions the retention times were 25.5, 32, 30, and 27 min for ()-
erythro-meﬂoquine, ()-erythro-meﬂoquine, ()-threo-meﬂoquine,
and ()-threo-meﬂoquine, respectively.
Studysampleswereprocessedinparallelwithasetofcalibrationstan-
dards(runintriplicate)preparedinblankmousebloodatconcentrations
of 0.05, 0.10, 0.50, 1.00, 5.00, and 10.00 g/ml. Calibration standard
curvesforeachmeﬂoquineanalogwerepreparedbyperformingweighted
(1/y) linear regression of the peak-height ratios (analog/internal stan-
dard) versus concentration. All of the experimental calibration curves
yielded coefﬁcient of determination (r
2) values of 0.985 or greater.
Statistical analysis. The statistical signiﬁcance of the differences in
tissue bacterial loads was assessed by analysis of variance (ANOVA). Dif-
ferences between experimental groups were considered signiﬁcant at P
values of 0.05.
RESULTS
Table 1 shows that the four meﬂoquine enantiomers had compa-
rable MICs in vitro against M. avium strains. The MIC was also
similar to the MIC obtained with meﬂoquine. Therefore, when
one adds bacterium and compound to a test device, the racemic
mixture and enantiomers behave similarly.
The postantibiotic effect (PAE) of ()-erythro-meﬂoquine
against three MAC isolates, however, was signiﬁcantly greater
thanthatofmeﬂoquinebothattheMICand4MIC(Table2).In
TABLE 1 MICs of 50% and 90% were determined using 30 strains for
M. avium, including 6 strains that are resistant to clarithromycin
Compound
MIC
50% 90%
()-Erythro-meﬂoquine 32 32
()-Erythro-meﬂoquine 32 32
()-Threo-meﬂoquine 32 64
()-Threo-meﬂoquine 64 64
Meﬂoquine 16 16
Clarithromycin 2 4
Moxiﬂoxacin 0.5 0.5
()-Erythro-Meﬂoquine against Mycobacterium avium
August 2012 Volume 56 Number 8 aac.asm.org 4203
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 comparison,()-erythro-meﬂoquinehadgreaterPAEthanclari-
thromycinattheMIC,butthePAEwassimilarwhenbacteriawere
exposed to the concentration of 4 MIC. Moxiﬂoxacin had PAE
of 2 h independent of the concentration used.
After intravenous administration, the half-lives (t1/2) for me-
ﬂoquine, ()-erythro, and ()-erythro-enantiomers were simi-
lar: 17.8 h, 16.7 h, and 20.6 h, respectively. The two threo-enan-
tiomers were both eliminated more rapidly than the parent
compound and the erythro-enantiomers. The t½ for ()-threo-
and ()-threo-enantiomers were 12.4 h and 11 h, respectively.
Following oral administration, the t1/2 were 16.3 h, 20.8 h, and
16.4hformeﬂoquine,()-erythro,and()-erythro-meﬂoquine,
respectively. After oral administration, the Cmax of meﬂoquine
was lower than the individual Cmax values of ()-erythro- and
()-erythro-enantiomers. The area under the curve (AUC) for
thethreecompoundswashigh.CmaxandAUCvaluesforthe()-
threo- and ()-threo-enantiomers were lower than for the other
three compounds. The bioavailabilities for all ﬁve compounds
ranged from 71 to 100% (Table 3).
Incontrasttotheinvitroresults,only()-erythro-meﬂoquine
exhibitedsigniﬁcantefﬁcacyagainstdisseminatedM.aviuminfec-
tion in mice (Fig. 1 and 2). The compound had signiﬁcant bacte-
ricidal activity in the spleen of infected mice. In addition, ()-
erythro-meﬂoquine was signiﬁcantly more efﬁcacious against M.
avium in mice than meﬂoquine in the liver (Fig. 1 and 2).
DISCUSSION
The previously reported anti-M. avium properties of meﬂoquine
prompted us to evaluate the enantiomers of meﬂoquine (6,7). Only
()-erythro-meﬂoquine was active in vivo against M. avium. What
could explain the different activities among the enantiomers in vivo?
The results obtained could be due to the different pharmacokinetic
properties of the enantiomers. Since the compounds were adminis-
teredorally,lackofabsorptioncouldexplainourﬁndings.However,
ourpharmacokineticdatadoesnotsupportthehypothesis.Infact,all
four enantiomers were absorbed and achieved measurable blood
concentrations, conﬁrming unpublished data in an experimental
modelofPlasmodiuminfectionwhichshowedthatbotherythro-and
threo-meﬂoquine are absorbed slowly in the intestinal tract. Addi-
tionally,thedistributionandmetabolismoftheenantiomerscouldbe
different.Ithasbeenreportedthatinrat,oraladministrationofrace-
mic meﬂoquine resulted in plasma concentrations of the ()-enan-
tiomer two to three times higher than those of the ()-enantiomer
(4). Our data showed that, in BALB/c mice, the t1/2 for the threo
compounds was half that of the erythro compounds, which could
explain,atleastinpart,ourﬁndings.Itshouldbenoted,however,that
pharmacokineticstudiesinhealthyhumanshaveshownthatthehalf-
life of ()-erythro-meﬂoquine is signiﬁcantly longer than that of
()-erythro-meﬂoquine; no stereoselectivity was seen for values of
timetomaximumconcentrationofdruginserum(Tmax)(18).Sim-
ilar results were observed in adults with uncomplicated multidrug-
resistant falciparum malaria, where the mean ratio between the con-
centrationsofthe()-and()-enantiomersoferythro-meﬂoquine
was 3.37 (12). In a study carried out in healthy Caucasian adults, the
half-life at 	 phase (t1/2	) was found to be 430.4 for ()-erythro-
meﬂoquineversus172.8for()-erythro-meﬂoquine,AUCatsteady
statewas197.3versus30.1,whiletheplasmaCmaxwas1.42versus0.26
(13). In addition, the concentration of ()-erythro-meﬂoquine in
venousbloodwashigherthaninplasma(1.41),whereastheopposite
(0.89) is seen for ()-erythro-meﬂoquine (14). None of these stud-
ies, however, reported data for the threo-enantiomers. These inter-
speciesdifferencescastdoubtonanypharmacokineticinterpretation,
since our data were collected in mice.
An alternative explanation could be that the enantiomers bind
TABLE 2 PAE was measured at MIC and 4 MIC of drug with an
exposure time of 24 h
Compound
PAE (h; mean 
 SD)
a
MIC 4 MIC
()-Erythro-meﬂoquine 36 
 24 1 
 3
()-Erythro-meﬂoquine ND ND
()-Threo-meﬂoquine ND ND
()-Threo-meﬂoquine ND ND
Meﬂoquine 25 
 12 5 
 2
Clarithromycin 28 
 44 2 
 3
Moxiﬂoxacin 2 
 0.5 2 
 1
a Against the strains MAC 101, MAC 104, and MAC 109. ND, not done.
TABLE 3 Pharmacokinetic characteristics of meﬂoquine and enantiomers after oral administration to BALB/c mice
b
Drug Route
Dose
(mg/kg)
a t½ (h) Tmax(h)
Cmax
(mg/ml)
AUC
(mg/h/ml)
V or V/F
(liter/kg)
Cl or Cl/F
(ml/h/kg) MRT (h) F (%)
Meﬂoquine i.v. 10 17.8 NA 1.58 23.69 10.8 422.2 22.5
p.o. 40 16.3 1.00 5.01 114.13 8.2 350.5 19.2 120
()-Erythro-meﬂoquine i.v. 6 28.2 NA 0.72 13.77 17.9 439.8 35.2
p.o. 24 20.6 2.00 2.07 57.23 12.6 423.3 25.4 104
()-Erythro-meﬂoquine i.v. 4 14.4 NA 0.87 10.42 7.9 378.5 21.1
p.o. 16 11.4 1.00 3.04 51.81 5.0 304.4 16.2 124
()-Erythro i.v. 10 16.7 NA 5.25 37.30 6.5 268.1 23.4
p.o. 40 20.8 4.00 5.38 186.23 6.4 214.8 30.8 125
()-Erythro i.v. 10 20.6 NA 5.51 49.83 6.0 200.7 25.0
p.o. 40 16.4 4.00 6.90 150.73 6.3 265.4 19.2 76
()-Threo i.v. 10 5.1 NA 1.82 8.99 8.1 1,112.0 7.2
p.o. 40 12.4 1.00 2.67 36.73 19.5 1,089.2 16.8 102
()-Threo i.v. 10 11.0 NA 2.28 20.27 7.3 493.3 15.1
p.o. 40 15.0 4.00 3.09 57.21 15.1 699.1 21.4 71
a The dose level for ()-erythro-meﬂoquine and ()-erythro-meﬂoquine in racemic meﬂoquine was adjusted for the distribution of enantiomers in meﬂoquine.
b N, not applicable; V, apparent volume of distribution; V/F, apparent volume of distribution after PO administration; Cl, total clearance; Cl/F, clearance after PO administration;
F, bioavailability after PO administration.
Bermudez et al.
4204 aac.asm.org Antimicrobial Agents and Chemotherapy
 
o
n
 
N
o
v
e
m
b
e
r
 
1
2
,
 
2
0
1
2
 
b
y
 
O
r
e
g
o
n
 
S
t
a
t
e
 
U
n
i
v
e
r
s
i
t
y
h
t
t
p
:
/
/
a
a
c
.
a
s
m
.
o
r
g
/
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 toatarget(s)inthebacteriumwithadifferentafﬁnity.Wecarried
out a DNA microarray assay comparing the response of an M.
avium strain (MAC 101) to the exposure to meﬂoquine and ()/
()-erythro-meﬂoquine (RTI-1188) (data not shown). The re-
sults varied signiﬁcantly between the two compounds (data not
shown)inagreementwiththepossibilitythatstereospeciﬁcitycan
be associated with inhibition of the bacterium growth.
In the study, BALB/c mice were used to evaluate the pharma-
cokinetic parameters, and beige mice were used for the efﬁcacy
studies. In our previous experience, those mouse strains did not
showtobedifferentfromeachother.Inaddition,thedailydoseof
meﬂoquine used is correspondent to the human dose. In the
mouse,theanti-M.aviumactivityofmeﬂoquineisseenwiththree
doses a week (7) but not with one, as used in humans as malaria
prophylaxis.
The discrepancy between the MIC in vitro and the activity in
the mouse can be explained by the superior pharmacological
properties of the erythro-enantiomers compared to those of the
threo-enantiomers and those of the ()-erythro-enantiomers
compared to those of the ()-erythro-enantiomers. In addition,
the dose used for the pharmacokinetic studies may have been re-
sponsible for some of the discrepancies, although the differences
obtained in t1/2 and AUC values between the threo- and erythro-
enantiomers cannot fully justify the difference in activities. We
haveunpublishedevidencethatoneofthedifferencesbetweenthe
()-erythro-meﬂoquine and the other enantiomers is probably
FIG 1 Effect of treatment of M. avium infection with meﬂoquine enantiomers on the bacterial load in the spleen. P values of 0.05 for comparisons between
meﬂoquine or ()-erythro-meﬂoquine and other experimental groups at both the same time point and at 1 week of infection.
FIG 2 Effect of treatment of M. avium infection with meﬂoquine enantiomers on the bacterial load in the liver. P values of 0.05 for comparisons between
meﬂoquine or ()-erythro-meﬂoquine and other experimental groups at both the same time points and at 1 week of infection.
()-Erythro-Meﬂoquine against Mycobacterium avium
August 2012 Volume 56 Number 8 aac.asm.org 4205
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 related to the better ability to concentrate in macrophages, since
()-erythro seems to be superior to the other enantiomers in the
macrophage system. The dose of 40 mg/kg corresponds to 10
times the dose of meﬂoquine in humans, but a correlation be-
tweenthedosesoftheenantiomerscannotbeestablished,because
they have not been evaluated in humans.
In light of the known neurotoxic effects associated with the
prophylactic use of meﬂoquine, our observation that the enan-
tiomer ()-erythro-meﬂoquine is the active anti-M. avium com-
pound in the racemic mixture may be extremely signiﬁcant. A
recent study has demonstrated that ()-meﬂoquine is excreted
more rapidly from brain than ()-meﬂoquine (3). The speciﬁc
neurotoxiceffectsof()-and()-meﬂoquineinhumanarecur-
rently not known; however, rapid excretion from the brain, taken
together with the greater efﬁcacy observed for ()-meﬂoquine,
could argue for an increased tolerance of ()-erythro-meﬂo-
quine.
The ﬁnding that ()-meﬂoquine is efﬁcacious in vivo against
M. avium suggests that use of the drug as a single enantiomers
would be beneﬁcial in terms of lower body burden and possibly
decreased human neuropsychiatric side effects. The preliminary
evaluation of toxicity of meﬂoquine and its enantiomers against
embryonic rat cell neurons in vitro showed that the ()-erythro-
enantiomer was approximately 47% less toxic than meﬂoquine
and()-erythro-meﬂoquineand87%and91%lesstoxicthanthe
()-threo- and ()-threo-meﬂoquine, respectively (data not
shown).
Finally, meﬂoquine has been used in the mouse model of My-
cobacterium tuberculosis and has shown to be quite effective in
combinationwithisoniazidandrifampin(17).Furtherevaluation
of this group of compounds may provide novel targets in M. tu-
berculosis.
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